Global Neuroblastoma Treatment Market Growth (Status and Outlook) 2023-2029

Global Neuroblastoma Treatment Market Growth (Status and Outlook) 2023-2029

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Neuroblastoma is a cancer that starts in primitive nerve cells. It rarely occurs after age around 10 years. Neuroblastoma is sometimes caused by a gene mutation passed from the parent to the child.

LPI (LP Information)' newest research report, the “Neuroblastoma Treatment Industry Forecast” looks at past sales and reviews total world Neuroblastoma Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Neuroblastoma Treatment sales for 2023 through 2029. With Neuroblastoma Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroblastoma Treatment industry.

This Insight Report provides a comprehensive analysis of the global Neuroblastoma Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroblastoma Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuroblastoma Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroblastoma Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroblastoma Treatment.

The global Neuroblastoma Treatment market size is projected to grow from US$ 434.3 million in 2022 to US$ 557.5 million in 2029; it is expected to grow at a CAGR of 3.6% from 2023 to 2029.

United States market for Neuroblastoma Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Neuroblastoma Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Neuroblastoma Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Neuroblastoma Treatment players cover Seattle Children’s, CureSearch, Texas Children’s, NANT, Sino Biopharmaceutical, Jiangsu Hengrui Medicine Co.,Ltd., Fosun Pharmaceutical, Novartis and Juno Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuroblastoma Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Combination Chemotherapy
Monoclonal Antibody Therapy
Vaccine Therapy
Chimeric Antigen Receptor T-Cell Immunotherapy
Oncolytic Virus Therapy

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Seattle Children’s
CureSearch
Texas Children’s
NANT
Sino Biopharmaceutical
Jiangsu Hengrui Medicine Co.,Ltd.
Fosun Pharmaceutical
Novartis
Juno Therapeutics
Kite Pharma
Adaptimmune

Please note: The report will take approximately 2 business days to prepare and deliver.